Today I sold all my 3500 stocks with 3000 USD loss. This Piece of trash stock with that Kind of rubbish Management will go under 3 USD soon. It was the same Situation in the 4's USD range....Dont trust theses liars. You will get 1 new Stock for 15 old stocks. This is the fact. They don't care about existing Investors. Quit as Long as you can! GL
MEGA OPP on this one .. SLNO (MC $25 M) BLOCKBUSTER in Phase 3 /Rare Disease +Orphan Status /$2+ BILLION Market /NO Debt = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $25 Million Cash: $8 Million Price $0.51
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Cempra To Combine With Melinta, To Add The Safest And Most Effective Fluoroquinolone Ever Developed
This is a companion/introductory article to one or more potentially future and more detailed articles bout the Cempra and Melinta merger. The new FDA guidance (
Lets Not Forget - Fusidic Acid | Bone and Joint Infection Clinical Trial. Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections. This study is ongoing, but not recruiting participants. Catalyst - Estimated Primary Completion Date- October 2017 (Final data collection date for primary outcome measure)
Abbott & Costello - The Niagara Falls Sketch (Slowly I Turned) - Amplified Volume
Is this merger beneficial for shareholders suggestions please
POS Zaccardelli, his partners in crime, and the corrupt BOD are all dumping their stocks. Wise up people!!!
Bail on the merger, dump management and get some competents in to run things!
they definitely not getting my approval for the merger unless they remove these parachutes. If I crash, you crash. play it fair incompetent management.
Can anyone enlighten me on the process and time frame of this reverse merger?
Many thanks in advance for your response.
Hard to believe how any of you longs can be surprised by the scoundrels running this dead company starting with "The Little Ape In Flats" and now incompetent Zaccardelli, his incompetent management and BOD.
This company has engaged in lies, fraud, and corruption from its inception. When the Soli P3 trial failed, what did management do? They gave themselves promotions and salary increases. By December of this year, they will have gone thru $80M with nothing to show for it except looking out for themselves.
Now they have given themselves golden parachutes and should all go to jail and you are surprised.
When a company tells you who they are, believe them. They made themselves very clear. They told you they were con men, and you still brought into their BS. You have nobody to blame but yourselves. This was a scam from day 1.
Management can write a book on how to destroy shareholder value, while paying themselves more money!!!
seriously? where is this incompetent management drove this company to? the sewers?
What does this company have other than cash? That will vanish after the "Golden Parachutes". I am surprised the founder of this company has not been sued by shareholders for withholding the liver enzyme debacle of the Antibiotic that was turned down by the FDA..
will this turd ever go go back up?
wonder what bacterial disease solithromycin and baxdela combo can cure
Im actually beginning to think the market for ABSSSI /MRSA may be twice as large as for CABP. 119,000 deaths for MRSA 59,000 for CABP. If Baxdella has twice the sales potential as Soli and we own half,then share price should be worth above $25 today.
I bet that a lot of lawsuits will be forthcoming, it's the old raiding of the coffers!!!